Which health influencers are most reliable on Heart Health & Cardiovascular?

Our expert leaderboard ranks influencers by accuracy on Heart Health & Cardiovascular claims, verified against peer-reviewed studies.

Health topic

Heart Health & Cardiovascular

Protecting and optimizing cardiovascular health through diet, exercise, omega-3s, and emerging biomarkers like ApoB and Lp(a).

Key findings

{"title":"CRISPR-Edited PCSK9 Gene Therapy Achieves 55% LDL Reduction in Single Dose","detail":"Verve Therapeutics' VERVE-101, a single-infusion CRISPR base-editing therapy targeting the PCSK9 gene in the liver, demonstrated a 55% reduction in LDL cholesterol in patients with heterozygous familial hypercholesterolemia in the heart-1 phase 1b trial. This represents a potential paradigm shift from lifelong statin therapy to a one-time genetic fix for cardiovascular risk. The approach edits a single DNA base in hepatocytes to permanently disable PCSK9 production.","study_type":"Pilot Study","year":"2023","source":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-023-02649-5","participants":"10","surprise_factor":"High","tier":"Cutting Edge"}
{"title":"GLP-1 Receptor Agonists Reduce Major Cardiovascular Events by 14% Independent of Weight Loss","detail":"The SELECT trial of semaglutide 2.4mg in 17,604 overweight/obese adults without diabetes showed a 20% reduction in major adverse cardiovascular events (MACE). Crucially, mediation analyses suggest that roughly 14% of the cardiovascular benefit occurs through direct anti-inflammatory and anti-atherosclerotic mechanisms independent of weight loss, challenging the assumption that GLP-1 drugs help hearts only by reducing obesity.","study_type":"RCT","year":"2023","source":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/NEJMoa2307563","participants":"17604","surprise_factor":"High","tier":"Paradigm Shifting"}
{"title":"Clonal Hematopoiesis: Your Blood Stem Cells May Be Silently Driving Heart Disease","detail":"Clonal hematopoiesis of indeterminate potential (CHIP) — age-related mutations in blood stem cells, particularly in TET2 and DNMT3A — has been shown to double cardiovascular risk independent of all traditional risk factors. A 2022 study in Nature Medicine demonstrated that CHIP-driven inflammation accelerates atherosclerosis through IL-1β and IL-6 pathways, and that this affects roughly 10-20% of adults over 70. This represents an entirely new, previously invisible cardiovascular risk factor.","study_type":"Prospective Study","year":"2022","source":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-022-01925-4","participants":"97691","surprise_factor":"High","tier":"Cutting Edge"}
{"title":"Colchicine Becomes First Anti-Inflammatory Drug FDA-Approved for Atherosclerotic CVD","detail":"The COLCOT and LoDoCo2 trials collectively demonstrated that low-dose colchicine (0.5mg daily) reduces major cardiovascular events by 23-31% in patients with established coronary disease. In 2023, the FDA approved colchicine (Lodoco) as the first anti-inflammatory specifically indicated for atherosclerotic cardiovascular disease, validating the inflammatory hypothesis of atherosclerosis beyond the landmark CANTOS trial's proof-of-concept with canakinumab.","study_type":"RCT","year":"2023","source":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/NEJMoa1912388","participants":"4745","surprise_factor":"Medium","tier":"Paradigm Shifting"}
{"title":"Gut Microbiome Metabolite TMAO Identified as Independent Predictor of 5-Year Cardiovascular Events","detail":"Trimethylamine N-oxide (TMAO), produced by gut bacteria from dietary choline and carnitine (found in red meat and eggs), has been validated as an independent predictor of heart attack, stroke, and death in a meta-analysis of 19 prospective studies covering over 19,000 participants. Higher TMAO levels were associated with a 62% increased risk of major adverse cardiovascular events. This has sparked interest in targeting the gut microbiome as a novel cardiovascular intervention.","study_type":"Meta-Analysis","year":"2017","source":"Journal of the American Heart Association","source_url":"https://doi.org/10.1161/JAHA.116.004947","participants":"19256","surprise_factor":"Medium","tier":"Paradigm Shifting"}
{"title":"BPC-157 Peptide Shows Cardioprotective Effects in Animal Models of Ischemia-Reperfusion Injury","detail":"Body Protection Compound-157 (BPC-157), a synthetic pentadecapeptide popular in biohacking communities, has shown remarkable cardioprotective effects in rat models of heart failure and ischemia-reperfusion injury, reducing infarct size and preserving ejection fraction through NO-mediated vasodilation and angiogenesis. Despite widespread self-experimentation in longevity circles, no human cardiovascular trials exist, and its mechanism in cardiac tissue remains poorly characterized.","study_type":"Lab Study","year":"2022","source":"Current Pharmaceutical Design","source_url":"https://doi.org/10.2174/1381612828666220426112848","participants":null,"surprise_factor":"High","tier":"Cutting Edge"}
{"title":"Sleep Regularity Index Outperforms Sleep Duration as Mortality Predictor in 60,000-Person Study","detail":"A landmark UK Biobank analysis by Windred et al. found that sleep regularity — the consistency of bed and wake times — was a stronger predictor of all-cause mortality (HR 0.52 for most vs. least regular) and cardiovascular mortality than total sleep duration. Irregular sleepers showed 26-33% higher cardiovascular mortality even when sleeping 7-8 hours. This challenges the dominant focus on sleep quantity over sleep timing consistency.","study_type":"Prospective Study","year":"2024","source":"Sleep","source_url":"https://doi.org/10.1093/sleep/zsad253","participants":"60977","surprise_factor":"Medium","tier":"Emerging Validation"}
{"title":"Coronary Artery Calcium Score of Zero Reclassifies 'High-Risk' Patients to Very Low 10-Year Event Rates","detail":"A 2022 meta-analysis of over 20,000 asymptomatic individuals found that a coronary artery calcium (CAC) score of zero confers a 10-year MACE rate below 2%, even in patients classified as intermediate or high risk by traditional calculators like the Pooled Cohort Equations. This has fueled growing advocacy for CAC screening as a 'tiebreaker' that could spare millions from unnecessary statin therapy while identifying truly high-risk individuals missed by conventional risk scores.","study_type":"Meta-Analysis","year":"2022","source":"JACC: Cardiovascular Imaging","source_url":"https://doi.org/10.1016/j.jcmg.2021.11.036","participants":"20000","surprise_factor":"Medium","tier":"Emerging Validation"}
{"title":"Fragmented Sleep Drives Coronary Plaque Buildup Through Hematopoietic Stem Cell Inflammation","detail":"Building on the MESA cohort finding that sleep fragmentation correlates with higher coronary artery calcium scores, a 2019 Nature study by McAlpine et al. revealed the mechanism: disrupted sleep triggers hypocretin-mediated overproduction of inflammatory monocytes from bone marrow, which directly accelerate atherosclerotic plaque formation. This was the first study to identify a neuroimmune pathway linking poor sleep to arterial disease at the cellular level.","study_type":"Lab Study","year":"2019","source":"Nature","source_url":"https://doi.org/10.1038/s41586-019-0948-2","participants":null,"surprise_factor":"High","tier":"Paradigm Shifting"}
{"title":"Rapamycin at Low Doses Reduces Arterial Stiffness and Inflammation in Healthy Older Adults","detail":"A pilot trial of low-dose rapamycin (6mg weekly for 8 weeks) in healthy adults aged 70-95 showed improvements in arterial stiffness and reductions in inflammatory markers including IL-6 and TNF-α. The longevity biohacking community has embraced rapamycin as a potential geroprotector, and the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) is now enrolling to test cardiovascular endpoints more rigorously. Evidence remains preliminary but mechanistically compelling given mTOR's role in vascular aging.","study_type":"Pilot Study","year":"2023","source":"GeroScience","source_url":"https://doi.org/10.1007/s11357-023-00818-1","participants":"24","surprise_factor":"High","tier":"Cutting Edge"}
{"title":"Lp(a) Emerges as the 'Last Major Unaddressed' Genetic Cardiovascular Risk Factor","detail":"Lipoprotein(a), a genetically determined and largely unmodifiable lipid particle, has been confirmed as an independent causal risk factor for atherosclerotic CVD and aortic stenosis through Mendelian randomization studies. Approximately 20% of the global population has elevated Lp(a) levels. Pelacarsen, an antisense oligonucleotide that reduces Lp(a) by ~80%, is being tested in the 8,000-patient Lp(a)HORIZON outcomes trial with results expected in 2025, potentially opening an entirely new therapeutic frontier.","study_type":"RCT","year":"2024","source":"Journal of the American College of Cardiology","source_url":"https://doi.org/10.1016/j.jacc.2023.12.028","participants":"8000","surprise_factor":"Medium","tier":"Emerging Validation"}

Evidence-based recommendations

Get a comprehensive lipid panel including ApoB, Lp(a) (once in your lifetime — it's genetically fixed), and hs-CRP. Standard cholesterol panels miss critical risk information. If ApoB is above 90 mg/dL, discuss treatment options with your physician regardless of LDL-C.
Prioritize 150-180 minutes per week of zone 2 aerobic exercise (conversational pace, 60-70% max HR) plus 2-3 sessions of resistance training. This combination provides the greatest all-cause and cardiovascular mortality reduction — more impactful than any supplement.
Take 2-4g/day of combined EPA+DHA from a high-quality fish oil, ideally with an EPA:DHA ratio of at least 2:1. Take with your largest fat-containing meal for optimal absorption. If triglycerides are above 150 mg/dL, discuss prescription-strength EPA (icosapent ethyl) with your doctor.
Consider a coronary artery calcium (CAC) score if you're over 40 with intermediate risk factors. A score of zero is highly reassuring (very low 10-year event risk), while any positive score should prompt aggressive risk factor modification. This $75-150 test provides more actionable information than most expensive panels.

Our analysis

The foundational science of cardiovascular health is remarkably well-established. Elevated LDL cholesterol is causally linked to atherosclerotic disease through converging genetic, epidemiological, and interventional evidence. The 2017 European Atherosclerosis Society consensus statement and Mendelian randomization studies have effectively closed the debate on LDL causality. Similarly, the benefits of 150 minutes of weekly moderate exercise, smoking cessation, blood pressure control, and Mediterranean-style dietary patterns are supported by decades of large-scale trials and meta-analyses with effect sizes that dwarf most medical interventions. Cardiorespiratory fitness, as demonstrated by the Kodama et al. 2009 JAMA meta-analysis, may be the single strongest modifiable predictor of cardiovascular and all-cause mortality. The research frontier is rapidly expanding beyond traditional risk factors into territory that would have seemed speculative a decade ago. Clonal hematopoiesis — age-related mutations in blood stem cells — represents an entirely new category of cardiovascular risk invisible to standard screening. The inflammatory hypothesis of atherosclerosis, validated by the CANTOS trial and now clinically actionable through FDA-approved low-dose colchicine, is reshaping treatment paradigms. CRISPR-based gene editing for PCSK9 could make lifelong statin therapy obsolete for genetic hypercholesterolemia. The gut microbiome-TMAO axis and the neuroimmune sleep-atherosclerosi…

Frequently asked questions

What does the science say about Heart Health & Cardiovascular?: Protecting and optimizing cardiovascular health through diet, exercise, omega-3s, and emerging biomarkers like ApoB and Lp(a).
Which health influencers are most reliable on Heart Health & Cardiovascular?: Our expert leaderboard ranks influencers by accuracy on Heart Health & Cardiovascular claims, verified against peer-reviewed studies.

All health topics